Innovative Therapies for Neurodegenerative Diseases

Dear Colleagues,

Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS) present significant medical challenges due to their irreversible progression and lack of curative treatments. In recent years, “innovative therapies” have emerged with the goal of not only alleviating symptoms but also modifying disease progression.

Neurodegenerative diseases have driven the exploration of innovative therapies, including nanotechnology, cellular therapy, gene therapy, and new pharmacological approaches. Nanotechnology enables the development of nanoparticles capable of crossing the blood-brain barrier, facilitating the direct delivery of drugs to affected neurons. Cellular and regenerative strategies involve the use of stem cells, direct and partial cellular reprogramming to restore neuronal function. Gene therapy and RNA interference have allowed for the modification of gene expression related to neurodegeneration, silencing those that contribute to the accumulation of toxic proteins in the brain. Additionally, new protein aggregation inhibitors, neuroinflammation modulators, and drugs targeting mitochondrial dysfunction have been developed to enhance energy production in neurons. These strategies represent significant advances in the fight against diseases such as Alzheimer’s and Parkinson’s, although further clinical trials are needed to validate their safety and efficacy.

The Special Issue of Pharmaceutics welcomes submissions on the following topics: pharmacological approaches, cellular therapies, nanotechnology, and neuroprotection strategies. The Special Issue of Biomedicines welcomes submissions focusing on molecular and cellular mechanisms underlying these diseases and therapeutic approaches. We invite researchers and healthcare professionals to submit their original studies or review articles with expert insights and perspectives in the field of therapeutic neuroscience.

You may choose our Joint Special Issue in Pharmaceutics.

Dr. Rosa María Giráldez-Pérez
Dr. María Victoria Naval
Dr. Javier Garcia-Pardo
Dr. Maria João Ramalho
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.